What is Erythropoiesis Stimulating Agents Market?
Erythropoiesis Stimulating Agents (ESAs) are used to increase the differentiation of progenitor cells to red blood cells in the treatment of anemia in chronic kidney disease to reduce transfusion requirements and anemia symptoms. The deficiency of iron is one of the major causes of anemia and insufficient red blood cells production. According to a secondary source, in United States, ~661,000 people are affected by kidney failures and 1.2 million people have HIV and this number is anticipated to increase in upcoming years. This will increase the demand for erythropoiesis stimulating agents in the country. To curb the rising incidence of anemia, demand for erythropoiesis stimulating agents is expected to increase over the coming years
The market study is being classified by Type (Epoetin Alfa, Epoetin Beta, Epoetin Omega, Epoetin Delta and Darbepoetin Alfa), by Application (Cancer, Renal Disorders, Anti-retroviral Treatment, Neural Diseases and Other) and major geographies with country level break-up.
Amgen Inc. (United States), Thermo Fisher Scientific (United States), Johnson and Johnson (United States), F. Hoffmann La Roche (Switzerland), Pfizer, Inc (United States), Celltrion, Inc (South Korea), BioSidus (Argentina), Intas Pharmaceuticals Ltd (India), Teva Pharmaceutical Industries Ltd (Israel), Ranbaxy Laboratories Ltd (India), LG Life Sciences Ltd. (South Korea), VHB Life Sciences Ltd. (India), Dr. Reddy’s Laboratories Ltd (India), Beijing Four Rings Bio-Pharmaceutical Co.,Ltd. (China) and Kyowa Kirin Co., Ltd. (Japan) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Zuventus Health Care (India), Serum Institute of India (India), Biocon Limited (India) and Shandong Kexing Bioproducts Co. Ltd (China).
The competitive nature of the key manufacturers involved in the global Erythropoiesis stimulating agents market has led to increasing their focus on continuous product development and partnership alliances to strengthen their market presence globally. Also, a growing number of third-party distributors and dealers will help in expanding the product reach and drive the manufacturer's revenue in the forecast period. Research Analyst at AMA predicts that United States and European Players will contribute to the maximum growth of Global Erythropoiesis Stimulating Agents market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Erythropoiesis Stimulating Agents market by Type, Application and Region.
On the basis of geography, the market of Erythropoiesis Stimulating Agents has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2019. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Occurrence of Chronic Kidney Disease (CKD)
- Rise in the End-stage Renal Disorder
- Growing Demand for Darbepoetin Alfa
- R&D Initiatives to Develop Cost-effective Solutions
- Use Of Erythropoiesis Stimulating Agents In Treating Parkinson’s Disease
- Stringent Regulatory Guidelines
- Growing Use of in Erythropoiesis in Treating HIV Infections
- Risks of Thrombosis During Surgery and Pure Red Cell Aplasia
- High Consumption of Erythropoietin Stimulating Agents in Emerging Economies
In October 2019, the companies named JCR Pharmaceuticals, Chong Kun Dang Holdings, and Dong-A ST Co., Ltd. received approval for sale of their darbepoetin alfa biosimilars products in the Japanese market. Darbepoetin alfa stimulates the production of red blood cells (erythropoiesis). The majority of patients in Japan are undergoing chronic dialysis is expected to have erythropoiesis-stimulating agents for the treatment.
U.S. Food and Drug Administration issued an advisory on the safety of erythropoiesis-stimulating agents darbepoetin alfa and epoetin alfa. The new safety information contains revised product labeling that includes updated warnings, a new boxed warning, and changes to dosing instructions. The boxed warning advises physicians to monitor hemoglobin levels and adjust the dose of erythropoiesis-stimulating agents to maintain hemoglobin levels needed to avoid blood transfusion.
Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Erythropoiesis Stimulating Agents Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry
Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase